Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical research study is to study the recommended dose of TROP2 CAR/IL-15 TGFBR2 KO NK cells that can be given intraperitoneally (infused directly into the stomach area) to participants with adenocarcinoma of the stomach that has spread to the peritoneum. The safety and effectiveness of this treatment will also be studied.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Chęć i możliwość udzielenia świadomej zgody na udział w badaniu
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu (skala ECOG 0 lub 1)
- •Potwierdzona histopatologicznie diagnoza raka żołądka (adenokarcinoma)
- •Rozpoznany rak żołądka w stadium IV z przerzutami do otrzewnej
- •Co najmniej 4 tygodnie od ostatniej chemioterapii
- •Zgoda na przebieg zabiegu chirurgicznego i pobrania próbek
- •Prawidłowa funkcja organów wewnętrznych
✗ Disqualifies
- •Wiek poniżej 18 lat
- •Kobiety w wieku rozrodczym niezastosowujące się do zaleceń antykoncepcyjnych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
UT MD Anderson
Houston, United States
Trial contact
Brian D Badgwell, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.